DE60325967D1 - Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen - Google Patents

Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen

Info

Publication number
DE60325967D1
DE60325967D1 DE60325967T DE60325967T DE60325967D1 DE 60325967 D1 DE60325967 D1 DE 60325967D1 DE 60325967 T DE60325967 T DE 60325967T DE 60325967 T DE60325967 T DE 60325967T DE 60325967 D1 DE60325967 D1 DE 60325967D1
Authority
DE
Germany
Prior art keywords
hematopoiese
immunocells
stimulation
vivo
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60325967T
Other languages
German (de)
English (en)
Inventor
Demao Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60325967D1 publication Critical patent/DE60325967D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/12—Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14—Calcium; Ca chelators; Calcitonin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60325967T 2002-05-29 2003-05-07 Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen Expired - Lifetime DE60325967D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/159,148 US7048922B2 (en) 2002-05-29 2002-05-29 Stimulation of hematopoiesis by ex vivo activated immune cells
PCT/US2003/014336 WO2004056397A1 (en) 2002-05-29 2003-05-07 Stimulation of hematopoiesis by ex vivo actived immune cells

Publications (1)

Publication Number Publication Date
DE60325967D1 true DE60325967D1 (de) 2009-03-12

Family

ID=29582827

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60325967T Expired - Lifetime DE60325967D1 (de) 2002-05-29 2003-05-07 Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen

Country Status (6)

Country Link
US (3) US7048922B2 (enExample)
EP (2) EP1511515B1 (enExample)
JP (1) JP4863620B2 (enExample)
DE (1) DE60325967D1 (enExample)
ES (1) ES2321189T3 (enExample)
WO (1) WO2004056397A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048922B2 (en) * 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
ATE496118T1 (de) * 2003-07-06 2011-02-15 Roger Williams Medical Ct Verfahren zur herstellung differenzierter hämatopoetischer zellen zur behandlung von zytopenie
JP2008512454A (ja) * 2004-09-10 2008-04-24 ヤング，デマオ 骨髄抑制患者に対する体外活性化細胞療法の構成と応用
US20060057121A1 (en) * 2004-09-10 2006-03-16 Demao Yang Compositions and treatments using ex vivo activated cells for myelosuppressed patients
US20080195007A1 (en) * 2007-02-12 2008-08-14 Yury Podrazhansky Method and device for using vibroacoustic stimulaton to enhance the production of adult stem cells in living organisms
GB0918615D0 (en) * 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20130071437A1 (en) * 2010-08-06 2013-03-21 Canine-Lab.Inc. Immunological function enhancing agent
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2015073918A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US12458249B2 (en) * 2018-03-29 2025-11-04 Demao Yang Cell therapy for patients
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12209689B2 (en) 2022-02-28 2025-01-28 Terumo Kabushiki Kaisha Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5047421A (en) 1984-01-26 1991-09-10 Oral-D Orally effective ion chelators
US5550161A (en) 1984-01-26 1996-08-27 Oral-D Substituted orally effective ION chelators related to deferoxamine
US5015664A (en) 1984-01-26 1991-05-14 Oral D Orally effective ion chelators related to deferoxamine
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5108760A (en) 1989-07-21 1992-04-28 Terumo Corporation Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
US5525232A (en) 1990-03-02 1996-06-11 The Liposome Company, Inc. Method for entrapment of cationic species in lemellar vesicles
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US5312831A (en) 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
EP0641776A3 (en) 1993-09-08 1997-05-02 Takeda Chemical Industries Ltd Thioglycerol derivatives.
AU1524095A (en) 1994-01-27 1995-08-15 Cellcor, Inc. Ex vivo activation of immune cells
US5631219A (en) 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6008042A (en) 1996-05-16 1999-12-28 Smithkline Beecham Corporation Interleukin-1 beta converting enzyme like apoptotic protease-7
US6010878A (en) 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
US5968513A (en) 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
WO1998006823A2 (en) 1996-08-14 1998-02-19 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
WO1998026747A2 (en) 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
US6231880B1 (en) 1997-05-30 2001-05-15 Susan P. Perrine Compositions and administration of compositions for the treatment of blood disorders
US5932446A (en) 1997-08-18 1999-08-03 Smithkline Beecham Corporation Hmvab41
CA2346769C (en) 1997-10-10 2004-09-14 The Regents Of The University Of California Implants comprising combinations of allogeneic cells for use in cancer treatment
EP1064354A4 (en) * 1998-03-20 2002-06-12 Genzyme Corp COMPOSITIONS AND METHODS FOR CAUSING T CELL RESPONSE WITH GENE-BASED VACCINES
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
WO2001034788A1 (en) 1999-11-10 2001-05-17 Yoreh Biotechnologies Ltd. In-vitro assay for assessment of cytotoxicity of a candidate agent
WO2001062092A1 (en) 2000-02-25 2001-08-30 Thomas Jefferson University Formulations and methods for using the same to elicit an immune response
AU2002218019A1 (en) 2000-11-03 2002-05-15 Nexell Therapeutics Inc. Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7332158B2 (en) 2002-05-29 2008-02-19 Demao Yang Compositions and treatments for myelosuppression by ex vivo activated immune cells
US7048922B2 (en) 2002-05-29 2006-05-23 Demao Yang Stimulation of hematopoiesis by ex vivo activated immune cells

Also Published As

Publication number Publication date
US7048922B2 (en) 2006-05-23
US20030223968A1 (en) 2003-12-04
JP4863620B2 (ja) 2012-01-25
EP1511515A1 (en) 2005-03-09
ES2321189T3 (es) 2009-06-03
EP2011863A1 (en) 2009-01-07
EP1511515B1 (en) 2009-01-21
US20050130303A1 (en) 2005-06-16
US20080292605A1 (en) 2008-11-27
WO2004056397A1 (en) 2004-07-08
JP2006514034A (ja) 2006-04-27
US7758857B2 (en) 2010-07-20

Similar Documents

Publication Publication Date Title
DE60325967D1 (de) Stimulierung von hämatopoiese bei ex vivo aktivierten immunzellen
DE602004023044D1 (de) Transthorakale Mehrwegdefibrillator und Kardioverter
ATE390898T1 (de) Zwischenwirbelimplantat
ATE394087T1 (de) Zwischenwirbelimplantat
ATE394086T1 (de) Zwischenwirbelimplantat
DK1437106T3 (da) Prøveimplantatsæt
DE50212417D1 (de) Knochenverankerungselement
DE60312054D1 (de) Prothese
NO2014008I2 (no) Linagliptin
DE60324178D1 (de) THIAZOLIDIN-4-ONES UM hYAK3 PROTEINEN ZU HEMMEN
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
DE60311298D1 (de) Kopfhautbehandlung
DE50311735D1 (de) Das tissue engineering von knochen
DE602004004262D1 (de) Ultraschallbehandlung von gewebematrices
DK1553950T3 (da) Terapeutisk behandling
DE60318819D1 (de) Hitzestabile mutanten von stärkebiosyntheseenzymen
DE60309255D1 (de) Abbildung und Entnahme von Gel
DE50211671D1 (de) Implantierbare Prothese
FI20021617A7 (fi) Diagnostisia ja terapeuttisia menetelmiä
DE60312992D1 (de) Medizinisches implantat
DE60318635D1 (de) Herzstimulationsvorrichtung
DE602004022100D1 (de) Stimulationshilfe
DE60304451D1 (de) Verwendung von ceramiden in haarbehandlungsmitteln
DE60326437D1 (de) Therapeutische verwendung von sapogeninen
NO20022747D0 (no) Behandlingsstol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition